AHR Notes

2026-06-03 Proteostasis PN review

Falcon deep research was attempted with just deep-research-falcon human AHR --fallback perplexity-lite. Falcon timed out after 600 seconds and the configured perplexity-lite fallback failed with a quota error, so no provider deep-research file was created. This review therefore uses the fetched UniProt/GOA files, cached publications, and the Proteostasis PN projection/mapping reports.
AHR is primarily a ligand-activated bHLH-PAS receptor/transcription factor. Ligand binding is directly supported by the human/mouse AHR mutagenesis study showing that the cDNA-encoded protein binds TCDD specifically PMID:7961644.
Activated AHR forms the AHR:ARNT transcription-factor complex and binds regulatory DNA. Structural work describes AHR and ARNT as a heterodimeric bHLH-PAS transcription factor and reports the DNA-bound AHR:ARNT structure [PMID:28602820 "AHR is activated by xenobiotics, notably dioxin"; PMID:28602820 "structural basis of AHR assembly and DNA interaction"].
AHR trafficking is part of the core activation cycle: inactive AHR is predominantly cytoplasmic, ligand binding stabilizes nuclear accumulation, and DNA/ARNT interaction is not required for the trafficking step itself PMID:34521881.
HSP90/p23/XAP2 binding is a real mechanistic part of the cytosolic AHR complex and should be retained as informative, unlike generic protein binding annotations PMID:11259606.
AHR has many downstream immune and disease-context roles. IL4I1-derived tryptophan catabolites activate AHR and suppress anti-tumor immunity, but these are context-dependent outputs rather than separate core molecular functions PMID:32818467.
The Proteostasis PN projection proposes GO:1990756 ubiquitin-like ligase-substrate adaptor activity for AHR from Ubiquitin Proteasome System|E3 ubiquitin and UBL ligases|Cul4A/Cul4B substrate adaptor, status new_to_goa [file:projects/PROTEOSTASIS/reports/pn_projection/pn_projected_candidate_additions.tsv "AHR GO:1990756 ubiquitin-like ligase-substrate adaptor activity new_to_goa"].
Conservatively, I did not accept the PN AHR projection. The specific AHR/ARNT/TBL3 subtype is no_mapping in the UPS mapping YAML, while the parent Cul4A/Cul4B substrate-adaptor group is flagged for manual gene-level review before any gene-review change [file:projects/PROTEOSTASIS/mappings/ubiquitin_proteasome_system.yaml "Cul4A/Cul4B substrate adaptor|AHR / ARNT / TBL3 complex|PAS"; file:projects/PROTEOSTASIS/reports/pn_mapping_audit/current_mapping_scrutiny.tsv "manual_gene_level_review_required_before_gene_review_change"]. Local evidence supports AHR proteasomal degradation and transcriptional regulation, but not direct AHR substrate-recruiting adaptor activity for a CUL4 ligase.

Falcon deep research findings (2026-06-07)

A newly generated Falcon (Edison) deep research report was reviewed and synthesized against the existing COMPLETE review. The report is consistent with the existing review and adds mostly newer primary/review literature plus mechanistic and translational detail. Key findings, emphasizing what is NEW relative to the current review:

Molecular function / structural mechanism (NEW primary reference): Crystal structures of AHR-ARNT-DNA complexes were solved with six distinct ligands (tapinarof, FICZ, benzo[a]pyrene, β-naphthoflavone, indigo, indirubin), revealing an unconventional assembly with intimate PAS-B–PAS-B association between AHR and ARNT; AHR's PAS-B domain uses eight conserved residues that dynamically rearrange to bind ligands via hydrophobic and π–π interactions, and a segment of AHR transitions from chaperone engagement to ARNT-heterodimer stabilization to form the transcriptionally competent complex PMID:39900897. This directly strengthens the existing nuclear-receptor-activity, heterodimerization, and DNA-binding annotations and pinpoints PAS-B as the principal ligand-binding pocket. According to PubMed, doi:10.1038/s41467-025-56574-7.
Biological process / immunology (NEW review reference): A 2025 Nature Reviews Drug Discovery review consolidates AHR as a physiological regulator of innate and adaptive immunity, modulated by diet, commensal flora, and metabolism in autoimmunity, cancer, and infection; reported context-dependent transcriptional outputs include cytokines such as IL-10, IL-17, and IL-22 and immunoregulatory modules (e.g., CD39/CD73 adenosinergic pathway) PMID:40247142. This supports (does not change) the existing KEEP_AS_NON_CORE immune-process annotations. According to PubMed, doi:10.1038/s41573-025-01172-x.
Cellular localization / activation cycle: Falcon reaffirms the resting cytosolic chaperone complex (HSP90 dimer, AIP/XAP2, p23, sometimes SRC) and ligand-triggered nuclear translocation, ARNT dimerization, XRE/DRE binding (consensus 5'-TNGCGTG-3', core GCGTG), and the canonical "AHR gene battery" (CYP1A1/1A2/1B1, AHRR, TIPARP). All already captured in the review; AHRR is a feedback repressor mentioned but not annotation-changing here. (Dawe & Di Meglio 2025, doi:10.3390/ijms26041618; Bahman et al. 2024, doi:10.3389/fimmu.2024.1421346)
Non-canonical signaling (consistent with existing notes, not annotation-changing): Falcon describes activated AHR assembling a CUL4B-based E3 ubiquitin ligase (CUL4B^AHR) targeting ER-α, AR, β-catenin, PPARγ, and acting as a cytoplasmic adaptor/scaffold linking SRC/JAK2 to PI3K-AKT, MEK-ERK, YAP-ERK. This matches the previously documented Proteostasis PN E3-adaptor question and is retained as an open question rather than an accepted annotation (review-only, kidney-focused review: Xie et al. 2024, doi:10.1186/s11658-024-00550-4).
Disease links / translational (context, not annotation-changing): Tapinarof (a topical AHR agonist) was FDA-approved (May 2022) for plaque psoriasis and is in trials for additional indications; benvitimod is approved in China; AHR antagonists (e.g., IK-175, BAY2416964) are in oncology development. Open Targets links AHR to atopic eczema and psoriasis. These are pharmacological/clinical and do not alter the GO core-function annotations PMID:40247142.

Provenance note: the two Nature-family papers above (Diao et al. 2025; Polonio et al. 2025) were resolved to PMIDs and exact titles via the PubMed MCP (DOI→PMID conversion). Other Falcon citations (Dawe 2025, Bahman 2024, Xie 2024, Elson & Kolluri 2023, Sahoo 2025, Mosa 2025) and ClinicalTrials.gov / Open Targets entries are recorded here as supporting context only and were not added to the YAML.